Fortrea Holdings Inc.
FTRE Small CapHealthcare · Biotechnology
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Fortrea Holdings Inc. en bref
Fortrea Holdings Inc. (FTRE) is currently trading at 13,35 € with a market capitalization of 1,3 Md €. The 52-week range spans from 3,80 € to 16,28 €; the current price is 18% below the yearly high. Year-over-year revenue growth stands at -2.3%.
💰 Dividende
Fortrea Holdings Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
11 analystes évaluent Fortrea Holdings Inc. (FTRE) au consensus : Acheter. L'objectif de cours moyen est de 14,13 €, soit un potentiel de +5.87% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 8,28 € à 17,44 €.
Fortrea Holdings Inc. : la thèse d'investissement en détail
Fortrea Holdings Inc. (FTRE) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario baissier
Revenue is contracting at -2.3% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. The debt-to-equity ratio of 212.7% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.
Valorisation en contexte
With a PEG ratio of 0.34, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 35.52x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.
Thèse d'investissement : forces et faiblesses
- Consensus des analystes : Buy
- Free cash flow positif
- –CA en contraction (-2.3% sur un an)
- –Actuellement non rentable
- –Endettement élevé (D/E 212.7)
- –Forte volatilité (Bêta 2.11)
- –Positions vendeuses élevées (11.79%)
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to above-average price swings, elevated short interest (11.79%), higher leverage relative to equity.
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Fortrea Holdings Inc.?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
